Lawrence B. Cohen’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lawrence B. Cohen’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,800	Closed	-$319K	–	9
2023 Q3	$319K	Hold	1,800	–	–	0.22%	52
2023 Q2	$342K	Hold	1,800	–	–	0.22%	55
2023 Q1	$361K	Hold	1,800	–	–	0.24%	52
2022 Q4	$428K	Hold	1,800	–	–	0.22%	74
2022 Q3	$360K	Hold	1,800	–	–	0.28%	55
2022 Q2	$263K	Hold	1,800	–	–	0.19%	56
2022 Q1	$294K	Hold	1,800	–	–	0.17%	54
2021 Q4	$305K	Hold	1,800	–	–	0.12%	79
2021 Q3	$340K	Hold	1,800	–	–	0.18%	63
2021 Q2	$305K	Buy	+1,800	New	+$264K	0.16%	65

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lawrence B. Cohen's ALNY Position: Q4 2023 in Review

Lawrence B. Cohen sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1,800 shares — an estimated $319K sold.

Lawrence B. Cohen first reported a position in ALNY in Q2 2021 and held it in 10 quarters. The position peaked at $428K in Q4 2022. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Lawrence B. Cohen reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Lawrence B. Cohen sold 1,800 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $319K.
Lawrence B. Cohen first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Lawrence B. Cohen's Alnylam Pharmaceuticals position peaked at $428K in Q4 2022.
498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Lawrence B. Cohen's 13F filing for Q4 2023, filed 9 Feb 2024.